1stOncology™: Cancer Intelligence Service – Page 9988 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Vor Biopharma Announces Pricing of Initial Public Offering

On February 5, 2021 Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, reported the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of $18.00 per share (Press release, Vor BioPharma, FEB 5, 2021, View Source [SID1234574708]). The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately $176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The shares are expected to begin trading on the Nasdaq Global Market on Friday, February 5, 2021, under the ticker symbol "VOR". The offering is expected to close on Tuesday, February 9, 2021, subject to customary closing conditions.

Goldman Sachs and Co. LLC, Evercore ISI, Barclays and Stifel are acting as joint book-running managers for the offering.

Registration statements relating to the securities being sold in this offering have been filed with the Securities and Exchange Commission (SEC) and have become effective. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the effective registration statements relating to these shares. Copies of the final prospectus may be obtained, when available, from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone at 1-866-471-2526, or via email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, via telephone at 1-888-474-0200, or via email at [email protected]; Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at 1-888-603-5847, or via email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, via telephone at 1-415-364-2720, or via email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work

On February 5, 2021 Bolt Biotherapeutics reported that it has raked in $230 million from its upsized IPO (Press release, Bolt Biotherapeutics, FEB 5, 2021, View Source [SID1234574707]).

One of the first immune-stimulating cancer drugs, prostate cancer vaccine Provenge, never quite lived up to expectations, but the scientist whose work led to the development of the product remains committed to immuno-oncology.

He’s Edgar Engleman, M.D., professor of medicine and pathology at Stanford University. His creation, Bolt Biotherapeutics, founded in 2015, recently launched its first clinical trial of its lead compound, which is part of a new class of cancer drugs called immune-stimulating antibody conjugates (ISACs). The drug is a tumor-targeting antibody that’s connected to an agent that stimulates the immune system.

In animal studies, the drug, which targets the tumor marker HER2, eradicated large tumors, according to a presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting in Maryland back in 2019. The drug also protected the animals from the development of new tumors, the company said.

That candidate, known as BDC-1001, is now in the clinic as a treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Bolt’s approach is different from a typical antibody-drug conjugate method of action, because its ISAC technology is based around the idea of connecting antibodies to agents that stimulate the immune system to attack the cancer rather than to compounds that directly poison cancer cells. And it’s designed to be able to be used as a solo therapy.

"We have designed BDC-1001 as a Boltbody ISAC comprised of a HER2-targeting biosimilar trastuzumab conjugated to one of our proprietary TLR7/8 agonists to maximize the potential anti-tumor response," the biotech said in its recent SEC-1 filing.

It started a phase 1/2 trial of BDC-1001 around a year ago and is currently in the dose-escalation portion of the trial; it expects to advance into phase 2 dose expansions in 2021 in "four clinically important and commercially compelling indications," it said.

"As of January 12, 2021, we have treated 19 patients and BDC-1001 appears to be well tolerated with mild to moderate adverse events and no dose-limiting toxicities, or DLTs, or drug-related serious adverse events observed to date. We have seen clinical activity in the form of stable disease, reductions in tumor volume and increases in pharmacodynamic markers that we believe are consistent with our proposed mechanism of action."

Bolt also has other, earlier preclinical programs, including one that focuses on CEA, a well-known tumor antigen that is overexpressed in various solid tumors with significant unmet medical need including, but not limited to, colorectal cancer, non-small cell lung cancer, pancreatic cancer and breast cancer. That could be in the clinic by next year.

It’s also at work on another early program for a PD-L1 Boltbody ISAC, which is targeting patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade.

The biotech will trade on the Nasdaq under the ticker "BOLT." The company previously filed for a $150 million IPO but, like so many in the past year, went well past this.

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab

On February 5, 2021 I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported the commencement of a proposed registered underwritten public offering by certain pre-IPO shareholders (the "Selling Shareholders") of American depositary shares (the "ADSs"), each ten (10) ADSs representing twenty-three (23) ordinary shares of the Company (Press release, I-Mab Biopharma, FEB 5, 2021, View Source [SID1234574698]). The Selling Shareholders propose to offer an aggregate of 3,283,950 ADSs (the "ADS Offering"). The Selling Shareholders will also grant the underwriters a 30-day option to purchase up to 492,590 additional ADSs.

The Company will not receive any proceeds from the sale of the ADSs by the Selling Shareholders.

BofA Securities, Inc., Piper Sandler & Co. and Cantor Fitzgerald & Co. act as joint bookrunners for the ADS Offering.

The ADS Offering is being made only by means of a prospectus supplement and the accompanying prospectus included in an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the "SEC") on February 5, 2021, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement dated February 5, 2021 are available on the SEC website at: View Source The final prospectus supplement will be filed with the SEC and will be available on the SEC’s website at: View Source When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, or by emailing [email protected]; Piper Sandler & Co., Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or by email: [email protected]; and Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 499 Park Avenue, 6th Floor, New York, New York, 10022 or by email at [email protected].

This announcement shall not constitute an offer to sell, or a solicitation of an offer to buy, the securities described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

On February 5, 2021 ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, reported that Chris Martin, Chief Executive Officer, will participate in a fireside chat at Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 10:00 a.m. ET (Press release, ADC Therapeutics, FEB 5, 2021, View Source [SID1234574696]).

A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

Bristol Myers Squibb to Participate in Guggenheim’s Virtual Healthcare Talks | 2021 Oncology Day

On February 5, 2021 Bristol Myers Squibb (NYSE: BMY) reported that the company will take part in a fireside chat at Guggenheim’s Virtual Healthcare Talks | 2021 Oncology Day, which will be webcast on Friday, February 12, 2021 (Press release, Bristol-Myers Squibb, FEB 5, 2021, View Source [SID1234574695]). Chris Boerner, Ph.D., Executive Vice President, Chief Commercial Officer will answer questions about the company at 12 p.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at View Source Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.